Venus Remedies has partnered with Infex Therapeutics to develop MET-X, an innovative metallo-beta-lactamase inhibitor, to ...

The deal grants Venus Remedies the rights to develop, register, and commercialise MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, in India. Currently, there are no approved MBL inhibitors ...

The agreement authorises Venus Remedies to spearhead the clinical development, registration, and commercialisation of MET-X, an innovative metallo-beta- lactamase (MBL) inhibitor ...

Venus Remedies is collaborating with UK-based Infex Therapeutics for the clinical development of MET-X, a metallo-beta-lactamase (MBL) inhibitor that helps reduce resistance to beta-lactam antibiotics ...

Our Bureau, Bengaluru Tuesday, February 25, 2025, 14:45 Hrs [IST] ...

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces today that its p ...

Learn more about whether Exact Sciences Corporation or Zai Lab Limited is a better investment based on AAII's A+ Investor ...

The drug – a combination of beta-lactam antibiotic aztreonam with beta-lactamase inhibitor avibactam – is the first drug of this type to get a green light from the European Commission to treat ...

Illinois Municipal Retirement Fund increased its stake in Innoviva, Inc. (NASDAQ:INVA – Free Report) by 2.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the ...

Emblaveo is a combination of aztreonam, a monobactam antibiotic, and avibactam, a beta-lactamase inhibitor that can restore the ability of aztreonam to fight the types of bacteria than can become ...